$9.74
0.00% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Lyell Immunopharma Inc Stock price

$9.74
+1.65 20.37% 1M
-3.74 27.72% 6M
-3.06 23.91% YTD
-42.06 81.20% 1Y
-328.06 97.12% 5Y
-328.06 97.12% 10Y
-328.06 97.12% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.00 0.00%
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Key metrics

Market capitalization $144.23m
Enterprise Value $-156.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.76
EV/Sales (TTM) EV/Sales -2,242.13
P/S ratio (TTM) P/S ratio 2,060.44
P/B ratio (TTM) P/B ratio 0.43
Revenue growth (TTM) Revenue growth -12.50%
Revenue (TTM) Revenue $70.00k
EBIT (operating result TTM) EBIT $-222.07m
Free Cash Flow (TTM) Free Cash Flow $-207.14m
Cash position $301.18m
EPS (TTM) EPS $-22.67
P/E forward negative
P/S forward 5,769.20
EV/Sales forward negative
Short interest 4.73%
Show more

Is Lyell Immunopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Lyell Immunopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Lyell Immunopharma Inc forecast:

3x Hold
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Lyell Immunopharma Inc forecast:

Hold
75%
Sell
25%

Financial data from Lyell Immunopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.07 0.07
13% 13%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
14% 14%
75,129%
- Research and Development Expense 175 175
4% 4%
250,386%
-204 -204
7% 7%
-291,457%
- Depreciation and Amortization 18 18
11% 11%
25,786%
EBIT (Operating Income) EBIT -222 -222
7% 7%
-317,237%
Net Profit -335 -335
47% 47%
-477,886%

In millions USD.

Don't miss a Thing! We will send you all news about Lyell Immunopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyell Immunopharma Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as ...
Neutral
GlobeNewsWire
10 days ago
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:0...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025. Lyell's lead clinical program, LYL314 (formerly known as IMPT-314), is an autolog...
More Lyell Immunopharma Inc News

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lynn Seely
Employees 224
Founded 2018
Website lyell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today